Conference abstract · 28 Aug 2017
CommentaryPublished 21 Jan 2022
The clinical fix for treating NSCLC
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Non-Small Cell Lung Cancer (NSCLC) is an exceptionally dangerous cancer, with a critical mortality and dreariness. With the improvement of growth immunotherapy, Illusory Antigen Receptor T Cells (CART) gets progressively consideration and accomplishes unmistakable commitments in the treatment of hematologic malignancies. CART treatment for NSCLC continues gradually and further explores should be researched. In our review, we performed bioinformatics examination to assess the critical job of CD147 in NSCLC. The articulation level of CD147 was distinguished in human NSCLC cell lines and NSCLC tissues. Cell cytotoxicity and cytokine discharge were performed to assess the viability of CD147-CART. We additionally built Cell-Inferred Xenograft (CDX) model and Patient-Determined Xenograft (PDX) model, which was utilized to additionally research the wellbeing and adequacy of CD147-CART in vivo. Our perceptions show that CD147 is a particular cancer antigen of NSCLC and assumes a fundamental part in NSCLC movement, which can be utilized as an objective for CART treatment in NSCLC. Significantly, CD147-CART cells have solid enemy of growth movement against NSCLC cells in vivo in both CDX and PDX models and no antagonistic incidental effects. Our discoveries show that CD147-CART immunotherapy for NSCLC is protected and successful, which is an ideal and promising clinical fix for treating NSCLC.
Keywords
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 2017
Predictive value of PKM2 expression in advanced non-small cell lung cancer patients (NSCLC) treated with front-line platinum-based chemotherapy
Conference abstract · 2016
A predictive model of lymph node disease for patients with clinical stage T1aN0-2M0 non-small cell lung cancer (NSCLC)
Research article · 2014
Hedgehog (Hh) Signaling is a Predictor of Clinical Outcome for Advanced Non-Small Cell Lung Cancer (NSCLC)
Article · 2 Jul 2024
Optimizing the methodology for calculating the 4DCT derived internal target volume in stereotactic radiotherapy for Non-Small Cell Lung Cancer (NSCLC)
More from this journal
The newest in Journal of Molecular Cancer.
Article · 29 Apr 2024
Unveiling cancer: Mechanisms, progress and future directions
Article · 28 Apr 2024
Transcriptomics: Unraveling gene expression for advanced genomic insights
Article · 27 Apr 2024
Molecular mechanisms of cancer: Insights into tumor biology and therapeutic advances
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Molecular Cancer
- SubjectGenetics & Molecular Biology
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Enya Janssens”

